Osteomyelitis is a debilitating bone infection that can result when MRSA invades bone tissue following surgery. Now a team of scientists at University of Missouri led by Elizabeth Loboa, Dean of UM’s College of Engineering, has created silver-coated scaffolds that are seeded with fat-derived stem cells that can be triggered to create bone. The silver ions stave off MRSA while generating new bone.
Diseases and conditions where stem cell treatment is promising or emerging. (See Wikipedia:Stem cell#Treatments). To discuss image, please see Template talk:Häggström diagrams (Photo credit: Wikipedia)
The news is full of stories about stem cells performing near-miraculous healings – miraculous in that they take advantage of the body’s own powerful abilities to heal itself. Now here’s another amazing development: technology for isolating and spraying a mist of one’s own stem cells onto burns – even second-degree burns – to heal them quickly and with little or no scarring.
A German company called RenovaCare (www.renovacareinc.com) has patented and is further developing its so-called CellMist™ and SkinGun™ technologies The company estimates the possible market for this technology at more than $45 billion, which includes a broad range of potential applications for conditions such as burns, chronic wounds, and skin disorders like vitiligo as well as for various cosmetic applications.
Learn more about this unique biotechnology in this behind-the-scenes video of the technology and before-and-after images of a patient’s recovery. The stem cell good news just keeps coming.
They’re not quite ready to call it a cure, according to Dr. Susan Goodin of the Big Ten Cancer Research Consortium. But researchers are very excited about the number of seemingly complete and relatively long-lived remissions they’re seeing in certain kinds of cancers using this new immunotherapy. Used alone and sometimes in combination with other drugs or modalities, the drugs are forcing a certain percentage of melanomas and smoking-induced lung cancers to yield. Read more about how Johns Hopkins is moving ahead with anti-PD-1 research.
English: James Earl “Jimmy” Carter (Photo credit: Wikipedia)
This is revolutionary thinking about a new way to tap into the astounding power of our own immune system to fight cancer. It doesn’t yet work consistently with all cancers or for all patients, according to Dr. Jeffrey Sosman of Robert H. Lurie Comprehensive Cancer Center of Northwestern University. A lot more research is needed on how to identify who can benefit and how to translate the principle into drugs for other types of cancers. But its effects can be near-miraculous for some – in one such instance, 91-year-old President Jimmy Carter’s brain tumors disappeared.
Here’s Boston’s Dana-Farber Cancer Center’s quick-and-dirty cartoon video about how the anti-PD-1 drug hooks up with the PD-L1 expression on the cancer cell (antigen).
Cost is said to be staggering for these new drugs. But according to Dr. Sosman, the cost has nothing to do with the science involved. It’s more a function of what the market will bear. And he said there are ways to get the drugs for patients who desperately need them but can’t afford them.
More dramatic progress in learning how to work with nature rather than against it.
Person using cell phone while driving. (Photo credit: Wikipedia)
Regardless of how you feel about texting as a main source of communication between people, you may be glad to learn that that method of reaching out to people with diabetes can significantly improve several aspects of self-care.
The tests so far have involved thousands of subjects, and researchers are planning an even bigger study – 1 million people in India where diabetes is even more rampant than in the U.S. So far the results are impressive – participants in the daily messaging programs get friendly, not pushy, reminders to take medicine, check their glucose, eat salads, avoid too much bread/rice, etc. And the programs are making a real difference. Read more about text messaging apps for diabetics on Philly.com.
Recently attended a 14-week course based on the book Being Mortal. In it we examined in detail all aspects of end-of-life scenarios, including the right to choose the timing of one’s own death.. It was a sobering look at how our health care system conspires to wrest from us the right to make independent choices for ourselves. In the U.S. we commit tremendous resources to extending life but pay comparatively little attention to planning and care that honors patients’ end-of-life wishes. As a result, too many people suffer unnecessary treatments and end up spending their final moments in hospitals instead of at home. A rising chorus of experts and authors say this needs to change.
The Center for Health Journalism will host a webinar on Thursday, Sept. 29, at 10 a.m. PT / 1 p.m. ET that will give an overview of the problem, discuss how changes to our health care system could help, and offer insights on how journalists might spur more conversations on how we approach death in America.
The panel will feature Prof. Leonard Schaeffer, the Judge Robert Maclay Widney chair and professor at the University of Southern California. Previously, Schaeffer served as the founding chairman and CEO of WellPoint (now Anthem), one of the nation’s largest health insurance companies. He’ll be joined by Ann Neumann, author of “The Good Death: An Exploration of Dying in America” (2016) and a visiting scholar at The Center for Religion and Media at New York University.
They met last weekend in Indianapolis – twelve of the traditional Big Ten (actually 14) universities with active #cancer centers. The group calls itself Big Ten Cancer Research Consortium (BTCRC), and they are serious about combining their research data and working together to speed progress against cancer in all its guises.
Cancer cells fool the human immune system into not recognizing them as invaders. Dramatic research breakthroughs in immunotherapy are mapping out how to cut through that shield and let the immune system do its job. Congratulations, members of the BTCRC. We can’t wait to hear more about how your collaboration is changing the game for cancer patients around the world.
Follow Big Ten Cancer Research Consortium on Twitter
Over a period of two-plus years researchers tested two groups of older people (60-90 years) who’d experienced at least two falls prior to the start of the study, according to a recent Lancet article. One group received treadmill training only, three times each week. The other group received the same treadmill training but with an added component of virtual reality (VR) – audio/visual presentation of winding pathways, obstacles and other challenges that required the participant to pay careful attention.
Results showed dramatic improvement in the rate of falls in the months after the experimental training among those in the treadmill-plus-VR as opposed to a virtually unchanged rate of falls among those who had treadmill-only training.
So cool the discoveries/breakthroughs that are being made in medicine today. Who knows how many of us will die just before they invent the drug or procedure or protocol that will save the life of someone with the same condition ten years later? But how do we finance these breakthroughs?
Besides the issue of getting new treatments through the R&D and approval process, there’s always the question of who will be willing to pick up the tab for them. As the U.S. moves to significantly reduce healthcare costs, everyone is worried that “the scientific trajectory towards more personalized treatments will be squelched by the countervailing pressure to pay only for treatments deemed most effective in large populations of patients.” How do insurance coverage decisions affect changes in the R&D and investment process? What influence can patient groups have on setting priorities in the research that may pit comparative treatment effectiveness against personalized medicine?
Cancer cells are incredibly flexible about promoting their own movement and growth in the body. They can travel through blood vessels as thin as spider silk. They even change their shape to do so, yet are still able to divide and cluster into colonies in those very skinny spaces. That spreading through the body is called metastasis, and it’s what makes cancer turn deadly.
Researchers are now putting nanotechnology to work to help decipher exactly how cancer cells perform this extraordinary feat. An article in Nanotechnology Now reports:
The researchers trapped live cancer cells in the tubular membranes and, with optical high- and super-resolution microscopy, could see how the cells adapted to the confined environment. Cell structures significantly changed in the nanomembranes, but it appeared that membrane blebbing — the formation of bulges — at the cells’ tips helped keep genetic material stable, an important requirement for healthy cell division.
One of the biggest promises of nanomedicine is that doctors will be able to deliver needed medications directly to a site within your body without negatively affecting other tissues. That’s still a moving target, though.
One of the most challenging obstacles is the density and opaqueness of human tissue such as blood vessel walls and organs. A recent study reported in ACS nano (American Chemical Society Nano) has revealed a way to more accurately track where nanoparticles go once inside the body by allowing visibility a little deeper into living tissue. A gel, injected into tissues removed from mice, linked all the molecules of the tissue together except for lipids – the substances responsible for making tissue opaque. Lipids washed easily away and “left the tissues clear but otherwise intact.”
Lest you picture a big chunk of clear material, the actual depth to which researchers could image nanoparticles was only 1 millimeter, but that’s 25 times deeper than with existing methods. The hope is that in addition to helping track nanoparticles, this approach will assist researchers with tissue engineering, implant and biosensor applications.
Slowly, we peel away one tiny layer at a time from the mysteries of nature.
Looking at how bioscience news affects business, higher education, government – and you and me